Bioventus Inc. Class A Common Stock earnings per share and revenue
On Nov 04, 2025, BVS reported earnings of 0.15 USD per share (EPS) for Q3 25, beating the estimate of 0.11 USD, resulting in a 29.09% surprise. Revenue reached 138.65 million, compared to an expected 139.58 million, with a -0.67% difference. The market reacted with a +15.09% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analysts forecast an EPS of 0.21 USD, with revenue projected to reach 157.12 million USD, implying an increase of 40.00% EPS, and increase of 13.32% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were Bioventus Inc. Class A Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Bioventus Inc. Class A Common Stock reported EPS of $0.15, beating estimates by 29.09%, and revenue of $138.65M, -0.67% below expectations.
How did the market react to Bioventus Inc. Class A Common Stock's Q3 2025 earnings?
The stock price moved up 15.09%, changed from $6.56 before the earnings release to $7.55 the day after.
When is Bioventus Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Mar 09, 2026.
What are the forecasts for Bioventus Inc. Class A Common Stock's next earnings report?
Based on 4
analysts, Bioventus Inc. Class A Common Stock is expected to report EPS of $0.21 and revenue of $157.12M for Q4 2025.